Portal de investigación
FASE III: EFECTOS DEL TRATAMIENTO CON UBLITUXIMAB EN LA ESCLEROSIS MÚLTIPLE (ESTUDIO ULTIMATE I).
Datos básicos
- Código:
- TG1101-RMS301
- Protocolo:
- TG1101-RMS301
- EUDRACT:
- 2017-000638-75
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2018
- Año de finalización:
- 2021
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.
Casado, MA; (...); Grp MULTIDEX-EMD
Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
Acute cerebral haematoma in the course of herpes simplex 1 encephalitis. A rare complication.
Veiga Canuto D; (...); Quiroz Tejada A
Letter. 10.1016/j.nrl.2019.12.002. 2021
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
An algorithm to predict intrathecal synthesis of IgG with high efficiency
Tortosa-Carreres, Jordi; (...); Casanova, Bonaventura
Meeting Abstract. 2023
An expanded parenchymal CD8+ T cell clone in GABA A receptor encephalitis.
Bracher A; (...); Dornmair K
Article. 10.1002/acn3.50974. 2020
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia, X; (...); Tort, M
Article. 10.7399/fh.11147. 2019
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab
Alcala, C.; (...); Casanova, B.
Meeting Abstract. 2021
Antimicrobial stewardship programme implementation in a medical ward
Ruiz, J; (...); Poveda, JL
Article. 2018
Antimicrobial stewardship programme in critical care medicine: A prospective interventional study
Ruiz, J; (...); Catellanos, A
Article. 10.1016/j.medin.2017.07.002. 2018
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.
Álvarez-Sánchez L; (...); Cháfer-Pericás C
Article. 10.3390/ijms24021226. 2023
Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
Lunemann JD; (...); Comabella M
Article. 10.1212/NXI.0000000000200270. 2024
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
Monreal, Enric; (...); Villar LM
Article. 10.1001/jamaneurol.2023.0010. 2023
Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort.
Boix Lago, A.; (...); Casanova Estruch, B.
Meeting Abstract. 2023
Automated Cervical Spinal Cord Segmentation in Real-World MRI of Multiple Sclerosis Patients by Optimized Hybrid Residual Attention-Aware Convolutional Neural Networks
Bueno, America; (...); Alberich-Bayarri, Angel
Article. 10.1007/s10278-022-00637-4. 2022
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Basal levels of serum neurofilament light in normal aging and multiple sclerosis patients
Gasque Rubio, R.; (...); Casanova Estruch, B.
Meeting Abstract. 2021
Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
Brain atrophy in relapsing optic neuritis is associated to anti-mog antibodies
Navarro Canto, L.; (...); Casanova Estruch, B.
Meeting Abstract. 2019
Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype
Canto, LN; (...); Estruch, BC
Article. 10.3389/fneur.2019.01157. 2019
Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.
Perez-Miralles, Francisco Carlos; (...); Casanova, Bonaventura
Article. 10.1002/brb3.2044. 2021
Brain signal intensity changes as biomarkers in amyotrophic lateral sclerosis
Vazquez-Costa, JF; (...); Sevilla, T
Article. 10.1111/ane.12863. 2018
Carretera perdida: imagen de la degeneracion neuronal secundaria
Montoya-Filardi, A.; (...); Polo, J. Carreres
Article. 10.1016/j.rx.2022.01.008. 2022
Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.
Quintanilla-Bordás C; (...); Casanova B
Article. 10.3389/fneur.2022.897275. 2022
Cavernous Sinus Thrombosis Secondary to Streptococcus Constellatus Pharynges
Jaramillo-Angel, Natalia; (...); Carceller, Miguel Armengot
Article. 10.1007/s12070-024-04511-3. 2024
Cerebrospinal fluid kappa free light chains and IgM index for diagnosis and prognosis in multiple sclerosis
Gil-Perotin, S.; (...); Casanova, B.
Meeting Abstract. 2021
Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study
Lacruz-Ballester, L.; (...); Casanova-Estruch, B.
Meeting Abstract. 2021
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study
Oreja-Guevara, Celia; (...); Rio, Jordi
Article. 10.1016/j.msard.2024.105787. 2024
Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model
Nogueras, A; (...); Calleja, MA
Letter. 10.1136/ejhpharm-2019-001905. 2019
Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels
Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2024.1477335. 2024
Clinical, demographic and laboratory data associated with PML risk in patients treated with natalizumab
Toboso, I; (...); Villar, LM
Meeting Abstract. 2017
Cognitive impairment in multiple sclerosis: diagnosis and monitoring.
Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco
Article. 10.1007/s10072-021-05165-7. 2021
Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder
Lopez-Soley, Elisabet; (...); Solana, Elisabeth
Meeting Abstract. 2022
Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder.
Lopez-Soley E; (...); Solana E
Article. 10.3390/jpm12050743. 2022
Collaborative model of home delivery program in haemophilia through an association of patients
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
Gil-Perotin S; (...); Casanova B
Article. 10.3389/fneur.2019.01008. 2019
Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients
Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco
Article. 10.1155/2024/1950913. 2024
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.
Medina-Polo J; (...); López-Fando L
Article. 10.1002/nau.24276. 2020
Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Consensus on early detection of disease progression in patients with multiple sclerosis
Meca-Lallana, Jose E.; (...); Oreja-Guevara, Celia
Article. 10.3389/fneur.2022.931014. 2022
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN
Trillo, JL; (...); Torres, C
Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA A receptor encephalitis.
Brändle SM; (...); Dornmair K
Article. 10.1073/pnas.1916337118. 2021
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
CSF chitinase 3-like-1 association with disability of primary progressive MS
Perez-Miralles, F; (...); Casanova, B
Article. 10.1212/NXI.0000000000000815. 2020
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Changes in Brain Volume in Specific Regions could be related to Disability Progression in Primary Progressive Multiple Sclerosis Patients
Miralles, FP; (...); Casanova, B
Meeting Abstract. 2019
Changes in brain volume in specific regions could predict worsening cognition in primary progressive multiple sclerosis
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis
Izquierdo Ayuso, G.; (...); Casanova Estruch, B.
Meeting Abstract. 2021
Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2018
Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis: A one-year follow-up
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: reversal by anti-tnfa treatment.
Balzano T; (...); Felipo V
Article. 10.1016/j.jhep.2019.01.008. 2020
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Deciphering Multiple Sclerosis Progression.
Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco Carlos
Review. 10.3389/fneur.2021.608491. 2021
Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project
Blade, J; (...); Lizan, L
Article. 10.1136/bmjopen-2017-018850. 2018
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.
Barreiro-Gonzalez, Antonio; (...); Casanova, Bonaventura
Article. 10.1159/000519772. 2022
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-018-3442-y. 2018
DISCOVER STUDY, FIRST ANALYSIS SPECIFIC FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS BURDEN AND COST IN SPAIN: INTERIM ANALYSIS RESULTS
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Brieva, Luis; (...); Moral, Ester
Article. 10.1016/j.msard.2022.103805. 2022
Disturbed Glucose Metabolism in Rat Neurons Exposed to Cerebrospinal Fluid Obtained from Multiple Sclerosis Subjects
Mathur, D; (...); Burgal-Marti, M
Article. 10.3390/brainsci8010001. 2018
Does benign multiple sclerosis exist?
Verdini Martinez, Laura; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Dynamic 18F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study
Quintanilla Bordas, Carlos; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks.
Barreiro-González A; (...); Casanova B
Article. 10.1007/s13760-020-01516-x. 2020
Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers
Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo
Article. 10.3390/ijms241814151. 2023
Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.
Meca-Lallana, J E; (...); Calles Hernandez, C
Article. 10.1016/j.nrleng.2021.06.006. 2023
Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study
Meca-Lallana, J. E.; (...); Hernandez, C. Calles
Article. 10.1016/j.nrl.2021.06.007. 2024
Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study
Oreja-Guevara, C.; (...); Meca-Lallana, J. E.
Meeting Abstract. 2021
Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan
Ribera, E; (...); Hernandez-Novoa, B
Article. 10.1016/j.eimc.2016.11.015. 2018
Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Eculizumab for a catastrophic relapse in NMOSD: case report.
Gorriz, David; (...); Casanova, Bonaventura
Article. 10.1007/s10072-023-06971-x. 2023
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE; (...); Llarena C
Article. 10.1007/s40120-023-00557-7. 2023
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
Alcala, Carmen; (...); Casanova, Bonaventura
Article. 10.1007/s00415-022-10989-0. 2022
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
Alcala, C; (...); Casanova, B
Article. 10.1007/s00415-018-8899-3. 2018
eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Megias-Vericat, JE
Meeting Abstract. 2018
Elevation of Chi3l1 in acute disseminated encephalomyelitis: implications in pathogenesis
Gil-Perotin, S; (...); Casanova-Estruch, B
Meeting Abstract. 2018
Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.
Quintanilla-Bordás C; (...); Pérez-Miralles FC
Case Reports. 10.3389/fimmu.2024.1465678. 2024
Escalation vs. Early Intense Therapy in Multiple Sclerosis.
Casanova, Bonaventura, Quintanilla-Bordas, Carlos, Gascon, Francisco
Article. 10.3390/jpm12010119. 2022
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.jneuroim.2024.578428. 2024
Exploratory analysis for the implementation of antineoplastic logarithmic dose banding
Albert-Mari, A; (...); Poveda-Andres, JL
Article. 10.1007/s11096-018-0714-9. 2018
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Glioblastoma versus solitary brain metastasis: MRI differentiation using the edema perfusion gradient
Aparici-Robles F; (...); Miguel Garcia-Gomez, Juan
Article. 10.1111/jon.12920. 2021
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12568. 2017
Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study
Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units
Article. 10.7399/fh.10935. 2018
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.
Castillo-Villalba, Jessica; (...); Casanova, Bonaventura
Article. 10.3389/fimmu.2022.827738. 2022
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Imaging of post-traumatic hearing loss.
Mazon, M; (...); Mas-Estelles, F
Article. 10.1016/j.rx.2017.07.005. 2018
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial
Zubizarreta, I; (...); Villoslada, P
Article. 10.1073/pnas.1820039116. 2019
Immune tolerance in patients with Multiple Sclerosis and Neuromyelitis Optica by peptide-loaded tolerogenic dendritic cells: final results of the phase 1b clinical trial and extension
Zubizarreta, I; (...); Villoslada, P
Meeting Abstract. 2019
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study
Meca-Lallana, Jose E.; (...); Maurino, Jorge
Article. 10.1007/s40120-022-00356-6. 2022
Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective
Meca-Lallana, Jose; (...); Maurino, Jorge
Meeting Abstract. 10.1016/j.jns.2021.118844. 2021
Impact of stigma in patients with primary progressive multiple sclerosis: a one-year follow-up
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.1159/000478969. 2018
Improvements in Quality of Life of Patients with Multiple Sclerosis receiving Alemtuzumab in Clinical Practice: LEMVIDA study
Meca Lallana, Jose; (...); Forner, Mireia
Meeting Abstract. 10.1212/WNL.0000000000202381. 2023
Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.
Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo
Article. 10.1186/s41687-024-00822-9. 2024
Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2023.104997. 2023
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis
Comabella, Manuel; (...); Luenemann, Jan D.
Article. 10.1007/s00415-024-12763-w. 2025
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.
Ruiz J; (...); Poveda JL
Article. 10.23736/S0026-4946.18.04978-2. 2018
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?
Ribes Garcia, Sara; (...); Bonaventura, Casanova Estruch
Article. 10.1016/j.msard.2023.105033. 2023
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
Leptomeningeal gadolinium enhancement in multiple sclerosis
Gascon-Gimenez, F; (...); Casanova, V
Meeting Abstract. 2019
Leptomeningeal gadolinium enhancement lesions in multiple sclerosis are not related to different brain volume measures
Garcia, F; (...); Casanova, B
Meeting Abstract. 2018
Long-term efficacy of alemtuzumab in multiple sclerosis: a real word multicenter Spanish experience
Rubio Alcantud, Almudena; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.
Barreiro-González A; (...); Casanova B
Article. 10.1016/j.jns.2020.117180. 2020
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Management of iodine contrast induced salivary gland swelling (sialadenitis): experiences from an observational study.
Saro-Buendía M; (...); Armengot Carceller M
Article. 10.1080/00016489.2022.2162121. 2023
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview
Garcia-Foncillas, J; (...); Gomez, MVP
Review. 10.1007/s40291-021-00544-4. 2021
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.
Munoz-San Martin, Maria; (...); Ramio-Torrenta, Lluis
Article. 10.1212/NXI.0000000000200069. 2023
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.
Fernandez-Megia, MJ; (...); Poveda Andrés JL
Article. 10.7399/fh.10793. 2018
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.
Pedrero Prieto, Manuel; (...); Casanova Estruch, Bonaventura
Article. 10.1007/s10072-023-07252-3. 2023
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.
Toboso I; (...); Villar LM
Article. 10.3389/fneur.2020.579438. 2020
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
Alcala, C.; (...); Casanova, B.
Article. 10.1007/s00415-021-10926-7. 2022
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.
Alcala Vicente, Carmen; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2022.991596. 2022
Oligoclonal M bands distinguish two MS populations based on neurofilament light chain levels in patients without inflammatory activity
Castillo, J.; (...); Casanova, B.
Meeting Abstract. 2022
Oligoclonal M bands unveil occult inflammation in multiple sclerosis.
Casanova B; (...); Pérez-Miralles F
Article. 10.1016/j.msard.2022.104118. 2022
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Poveda, JL
Meeting Abstract. 2018
Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.
Coret F; (...); Casanova B
Article. 10.1177/2055217318783347. 2018
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
Meca-Lallana, JE; (...); Maurino, J
Article. 10.2147/PPA.S305707. 2021
Perception of stigma in patients with primary progressive multiple sclerosis.
Pérez-Miralles F; (...); Casanova-Estruch B
Article. 10.1177/2055217319852717. 2019
Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study)
Lallana, Jose Meca; (...); Maurino, Jorge
Meeting Abstract. 2021
Peripapillary retinal nerve fibre layer correlates better with spinal cord volume than with brain parenchymal fraction in multiple sclerosis
Barreiro-Gonzalez, A; (...); Casanova, B
Meeting Abstract. 2019
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Pilot evaluation of home delivery programme in haemophilia
Megias-Vericat, JE; (...); Poveda-Andres, JL
Article. 10.1111/jcpt.12718. 2018
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
Post-stapedectomy intravestibular luxation of the stapes
Fornas, Marta Navarro, Vernetta, Carlos de Paula, Polo, Joan Carreres
Editorial Material. 10.1016/j.otorri.2021.08.001. 2022
Post-stapedectomy intravestibular luxation of the stapes.
Navarro Fornas, Marta, de Paula Vernetta, Carlos, Carreres Polo, Joan
Editorial Material. 10.1016/j.otoeng.2022.07.001. 2022
Potential Biomarkers Associated with Multiple Sclerosis Pathology.
Mathur, Deepali; (...); Casanova, Bonaventura
Article. 10.3390/ijms221910323. 2021
Potential Role of CHI3L1+ Astrocytes in Progression in MS.
Cubas-Núñez L; (...); Casanova B
Article. 10.1212/NXI.0000000000000972. 2021
Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process
Valero, S; (...); Poveda, JL
Article. 10.1016/j.yrtph.2018.03.001. 2018
Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2024.105734. 2024
Predictive value of isolated CSF NfL and Chi3l1 measures in clinical practice
Gil-Perotin, S; (...); Casanova-Estruch, B
Meeting Abstract. 2018
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report
Gil-Perotin, S; (...); Casanova-Estruch, B
Article. 10.3389/fneur.2018.00340. 2018
Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker
Perez-Alenda, S; (...); Querol, F
Letter. 10.1111/hae.13388. 2018
Quantifying the patient ' s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
Meca-Lallana, JE; (...); Ballesteros, J
Article. 10.1371/journal.pone.0255317. 2021
Quantifying the patient's perspective in neuromyelitis optica spectrum disorders: design of a multicenter, non-interventional study
Meca-Lallana, J; (...); Maurino, J
Meeting Abstract. 2020
Radiological evaluation of the postsurgical middle ear.
Mazon, M.; (...); Carreres-Polo, J.
Article. 10.1016/j.rx.2021.04.005. 2021
Radiological evaluation of the postsurgical middle ear.
Mazón M; (...); Carreres-Polo J
Article. 10.1016/j.rxeng.2021.04.006. 2021
Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.
Ramo-Tello, Cristina; (...); Rovira À
Article. 10.3390/jpm12010006. 2021
Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease
Alcala, C; (...); Casanova, B
Editorial Material. 10.1016/j.msard.2018.12.005. 2019
Relationship between different cerebrospinal fluid biomarkers in multiple sclerosis: meaning and use in clinical practice
Castillo, J; (...); Casanova, B
Meeting Abstract. 2017
Renal function influences serum neurofilament light chain levels in patients with multiple sclerosis
Gasque Rubio, R.; (...); Casanova Estruch, B.
Meeting Abstract. 2022
Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.
Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco
Article. 10.1007/s10072-024-07772-6. 2024
Risk of transition to secondary progressive multiple sclerosis and accumulation of disability in progressive multiple sclerosis are not influenced by current therapies
Alcala, C; (...); Casanova, B
Meeting Abstract. 2017
Role of Imaging in pseudotumor cerebri syndrome
Veiga-Canuto, D, Carreres-Polo, J
Article. 10.1016/j.rx.2020.05.007. 2020
Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.
Article. 10.1111/ajt.14580. 2018
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
Arrambide, Georgina; (...); Meca-Lallana, Jose E
Article. 10.1212/NXI.0000000000001024. 2021
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Fissolo, Nicolas; (...); Comabella, Manuel
Article. 10.1136/jnnp-2023-332251. 2023
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
Monreal E; (...); Villar LM
Article. 10.1093/brain/awae260. 2024
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels at Disease Onset for Prediction of the Risk of Disability Worsening in Patients with Multiple Sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2023
Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2024
Serum Neurofilament Light Chain is a surrogate marker of NEDA-3 in Multiple Sclerosis
Gascon Gimenez, Francisco Guillermo; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).
Pérez-Miralles F; (...); Casanova B
Article. 10.1016/j.msard.2021.102860. 2021
Silent Progression or Bout Onset Progressive Multiple Sclerosis?
Gil-Perotin, S; (...); Casanova, B
Letter. 10.1002/ana.25537. 2019
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Spinal cord atrophy but not brain atrophy measures, correlates with the Multiple Sclerosis Severity Score
Carratala, S; (...); Estruch, BC
Meeting Abstract. 2018
Sustained hyperammonemia induces TNF-a IN Purkinje neurons by activating the TNFR1-NF-?B pathway.
Balzano T; (...); Felipo V
Article. 10.1186/s12974-020-01746-z. 2020
Symptom severity in Neuromyelitis Optica Spectrum Disorder from the patients' perspective
Meca-Lallana, J.; (...); Maurino, J.
Meeting Abstract. 2021
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The impact of stigma in people with primary progressive multiple sclerosis
Perez-Miralles, F; (...); Casanova-Estruch, B
Meeting Abstract. 2018
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus
Torrent-Farnell, J; (...); Lizan, L
Article. 10.1016/j.healthpol.2018.03.002. 2018
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Tracheobronchial Laceration After Blunt Chest Trauma.
Veiga Canuto D, Carreres Polo J
Article. 10.1016/j.arbres.2019.11.029. 2021
Tracheobronchial Laceration After Blunt Chest Trauma.
Veiga-Canuto D, Carreres-Polo J
Article. 10.1016/j.arbr.2021.05.007. 2021
Transient reduced diffusion on magnetic resonance imaging due to transneuronal degeneration of the striatum.
Belloch-Ripollés V, Carreres-Polo J
Case Reports. 10.33588/rn.7504.2022035. 2022
Transient restriction of diffusion in magnetic resonance imaging due to transneuronal degeneration of the corpus striatum
Belloch Ripolles, Vicente, Carreres-Polo, Joan
Editorial Material. 2022
Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience
Alcala, C.; (...); Casanova, B.
Meeting Abstract. 2021
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
Gascon-Gimenez, Francisco; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2023.1060696. 2023
Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.
Landete, Lamberto; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2021.727586. 2021
Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe
Alcala, C; (...); Casanova, B
Meeting Abstract. 2018
Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe
Alcala, C; (...); Casanova, B
Article. 10.1007/s00415-019-09195-2. 2019
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy
Garcia, SV; (...); Andres, JLP
Article. 10.1016/j.yrtph.2018.10.002. 2018
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
Usefulness of susceptibility-weighted imaging in subacute cerebral fat embolism
Gil-Perotin, S, Carreres-Polo, J
Letter. 10.1016/j.nrleng.2019.01.005. 2019
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023